AGCO Corporation vs Cytokinetics Inc — how do they compare? AGCO Corporation trades at $101.05 (market cap $7.10B), while Cytokinetics Inc trades at $76.55 (market cap $10.63B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and AGCO Corporation pays a 1.18% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| AGCO | CYTK | |
|---|---|---|
Market Cap | $7.10B | $10.63B |
Sector | Industrials | Technology |
52-Week High | $140.49 | $87.26 |
52-Week Low | $100.14 | $34.31 |
Enterprise Value | $9.37B | $10.74B |
Dividend Yield | 1.18% | — |
Signals from Pluang's Aura AI — not financial advice
AGCO Corporation (NYSE: AGCO) is trading at $100.87, down 1.91% on the day, following disappointing Q2 2026 earnings that missed expectations. The agricultural equipment manufacturer faces bearish technical signals with support at $99 and resistance at $103. Fundamentally, the company maintains reasonable valuation metrics (P/E 14.03, P/S 0.72) despite recent earnings volatility, with 2025 revenue of $10.08 billion and net income of $726.5 million. Recent leadership changes and multiple securities investigations have created investor uncertainty.
The outlook remains cautious as AGCO navigates weaker industry demand and lowered 2026 guidance. While analyst consensus suggests 23.5% upside to the $124.63 price target, near-term headwinds from agricultural market softness and legal scrutiny present significant risks. The stock's current valuation may offer value for patient investors, but execution risks and market sentiment require careful monitoring.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Trailing returns across standard periods
Latest headlines on both assets
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →